Effect of interferon-α on cortical glutamate in patients with hepatitis C: A proton magnetic resonance spectroscopy study

Psychological Medicine

Volumn 44, Issue 4, 2014, Pages 789-795

  Taylor, M J ^a,b   Godlewska, B ^a   Near, J ^a,c   Christmas, D ^d   Potokar, J ^d   Collier, J ^e   Klenerman, P ^f,g   Barnes, E ^f,g   Cowen, P J ^a  

^a WARNEFORD HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^f NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Depression; Glutamate; Glutamine; Hepatitis C; Interferon

Indexed keywords

ALPHA INTERFERON; DIAGNOSTIC AGENT; GLUTAMIC ACID; GLUTAMINE; PROTON;

ADULT; ARTICLE; BIOSYNTHESIS; BRAIN CORTEX; DEPRESSION; DRUG EFFECT; FEMALE; HEPATITIS C; HUMAN; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSIOLOGY;

ADULT; CEREBRAL CORTEX; DEPRESSION; FEMALE; GLUTAMIC ACID; GLUTAMINE; HEPATITIS C; HUMANS; INFLAMMATION; INTERFERON-ALPHA; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROTONS;

EID: 84896473737     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291713001062     Document Type: Article

References (34)

1. Alcaro A, Panksepp J, Witczak J, Hayes DJ, Northoff G (2010). Is subcortical-cortical midline activity in Depression mediated by glutamate and GABA?. A cross-species translational approach. Neuroscience and Biobehavioral Reviews 34, 592-605
2. Bonaccorso S, Meltzer H, Maes M (2000). Psychological and behavioural effects of interferons. Current Opinion in Psychiatry 13, 673-677
3. Byrnes V, Miller A, Lowry D, Hill E, Weinstein C, Alsop D, Lenkinski R, Afdhal NH (2012). Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition. Journal of Hepatology 56, 549-556
4. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R (2002). Association between Decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Molecular Psychiatry 7, 468-473
5. Constant A, Castera L, Dantzer R, Couzigou P, de Ledinghen V, Demotes-Mainard J, Henry C (2005). Mood alterations during interferon-Alfa therapy in patients with chronic hepatitis C: Evidence for an overlap between manic/ hypomanic and depressive symptoms. Journal of Clinical Psychiatry 66, 1050-1057
6. Danbolt NC (2001). Glutamate uptake. Progress in Neurobiology 65, 1-105
7. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL (2010). A meta-Analysis of cytokines in major depression. Biological Psychiatry 67, 446-457
8. First MB, Spitzer RL, Gibbon M, Williams JBW (2002). Structured Clinical Interview for DSM-IV-TR Axis I Disorders. Biometrics Research, New York State Psychiatric Institute; New York
9. Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD (2001). Evidence for a cerebral effect of the hepatitis C virus. Lancet 358, 38-39
10. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ, Schultz RL, Valentine AD, Meyers CA, Howell CD (2002). A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Molecular Psychiatry 7, 942-947
11. Häussinger D, Laubenberger J, vom Dahl S, Ernst T, Bayer S, Langer M, Gerok W, Hennig J (1994). Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology 107, 1475-1480
12. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989). The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Archives of Neurology 46, 1121-1123
13. Kupfer DJ, Frank E, Phillips ML (2012). Major depressive disorder: New clinical, neurobiological, and treatment perspectives. Lancet 379, 1045-1055
14. Leutscher PDC, Lagging M, Buhl MR, Pedersen C, Norkrans G, Langeland N, Morch K, Farkkila M, Hjerrild S, Hellstrand K, Bech P (2010). Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 52, 430-435
15. Lim C, Olson J, Zaman A, Phelps J, Ingram KD (2010). Prevalence and impact of manic traits in Depressed patients initiating interferon therapy for chronic hepatitis C infection. Journal of Clinical Gastroenterology 44, e141-e146
16. Mardini H, Smith FE, Record CO, Blamire AM (2011). Magnetic resonance quantification of water and metabolites in the brain of cirrhotics following induced hyperammonaemia. Journal of Hepatology 54, 1154-1160
17. McNally L, Bhagwagar Z, Hannestad J (2008). Inflammation, glutamate, and glia in Depression: A literature review. CNS Spectrums 13, 501-510
18. Mekle R, Mlynárik V, Gambarota G, Hergt M, Krueger G, Gruetter R (2009). MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3 T and 7 T. Magnetic Resonance in Medicine 61, 1279-1285
19. Miller AH, Maletic V, Raison CL (2009). Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biological Psychiatry 65, 732-741
20. OngÜr D, Jensen JE, Prescot AP, Stork C, Lundy M, Cohen BM, Renshaw PF (2008). Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biological Psychiatry 64, 718-726
21. Provencher SW (1993). Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magnetic Resonance in Medicine 30, 672-679
22. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB (2003). The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biological Psychiatry 54, 573-583
23. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH (2005). Depression During pegylated interferon-Alpha plus ribavirin therapy: Prevalence and prediction. Journal of Clinical Psychiatry 66, 41-48
24. Raison CL, Capuron L, Miller AH (2006). Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends in Immunology 27, 24-31
25. Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G, Spivey JR, Saito K, Miller AH (2010). CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-Alpha; relationship to CNS immune responses and depression. Molecular Psychiatry 15, 393-403
26. Rajkowska G, Miguel-Hidalgo JJ (2007). Gliogenesis and glial pathology in Depression. CNS and Neurological Disorders - Drug Targets 6, 219-233
27. Sanacora G, Zarate CA, Krystal JH, Manji HK (2008). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery 7, 426-437
28. Spielberger CD, Gorsuch RL, Lushene RE (1970). The State-Trait Anxiety Inventory: Test Manual. Consulting Psychologist Press: Palo Alto, CA.
29. Strakowski SM, Adler CM, Almeida J, Altshuler LL, Blumberg HP, Chang KD, DelBello MP, Frangou S, McIntosh A, Phillips ML, Sussman JE, Townsend JD (2012). The functional neuroanatomy of bipolar disorder; a consensus model. Bipolar Disorders 14, 313-325
30. Tavares RG, Tasca CI, Santos CES, Alves LB, Porciuncula LO, Emanuelli T, Souza DO (2002). Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochemistry International 40, 621-627
31. Théberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J, Neufeld RW, Rogers J, Pavlosky W, Schaefer B, Densmore M, Al-Semaan Y, Williamson PC (2002). Glutamate and glutamine measured with 4.0 T proton MRS in never-Treated patients with schizophrenia and healthy volunteers. American Journal of Psychiatry 159, 1944-1946
32. Wichers MC, Maes M (2004). The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-Alpha-induced depression. Journal of Psychiatry and Neuroscience 29, 11-17
33. Wijtenburg SA, Knight-Scott J (2011). Very short echo time improves the precision of glutamate detection at 3 T in 1H magnetic resonance spectroscopy. Journal of Magnetic Resonance Imaging 34, 645-652
34. YÜksel C, ÖngÜr D (2010). Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biological Psychiatry 68, 785-794